T of 40 individuals. The study protocol was authorized by the Comitato Etico Unico della Provincia di Ferrara ethical committee, and written informed consent was obtained from all patients. All participants included inside the study had been anonymized by utilizing sample identifiers that couldn’t be related to any person.Sufferers. Principal tumors and their matched metastases had been collected from 40 sufferers with ER+ metastaticDNA extraction.Archival formalin-fixed and paraffin-embedded (FFPE) tissue blocks were retrieved, whereupon 10 m sections have been stained with hematoxylin and eosin and have been then macrodissected to obtainSCIENtIFIC RePORTS (2018) 8:4371 DOI:ten.1038/s41598-018-22312-xwww.nature.com/scientificreports/Mutation in plasma after E-Ice-COLD Sample S-26 S-26 S-26 S-27 S-28 S-29 S-31 S-51 S-60 S-74 S-80 S-81 S-84 S-85 S-86 S-87 S-88 S-89 S-90 S-91 S-94 S-96 S-97 S-98 S-99 S-100 S-101 S-102 S-103 S-104 S-105 S-106 S-107 S-108 S-109 S-110 S-111 S-112 S-113 S-114 S-115 S-116 S-117 S-118 S-119 S-120 S-121 S-122 S-123 S-124 S-125 S-126 S-127 S-128 Blood sampling date 19-Jun-15 13-May-16 28-Mar-17 17-May-16 17-May-16 27-May-16 15-Sep-16 1-Sep-16 29-Aug-16 20-Sep-16 2-Nov-16 2-Nov-16 15-Nov-16 15-Nov-16 15-Nov-16 15-Nov-16 16-Nov-16 16-Nov-16 16-Nov-16 16-Nov-16 30-Nov-16 12-Dec-16 21-Dec-16 16-Dec-16 16-Dec-16 3-Mar-17 7-Mar-17 7-Mar-17 16-Mar-17 16-Mar-17 Piclamilast Inhibitor 24-Mar-17 24-Mar-17 24-Mar-17 24-Mar-17 24-Mar-17 28-Mar-17 28-Mar-17 29-Mar-17 29-Mar-17 29-Mar-17 29-Mar-17 4-Apr-17 4-Apr-17 5-Apr-17 5-Apr-17 6-Apr-17 6-Apr-17 6-Apr-17 7-Apr-17 11-Apr-17 11-Apr-17 11-Apr-17 11-Apr-17 4-May-17 Varianta None p.Y537S p.Y537S None p.L536H None p.Y537S None None None None p.Y537S None None p.Y537S p.Y537S p.Y537S None None p.D538G p.L536H None None p.D538G None None p.D538G p.D538G None p.Y537H None None None None None None None p.Y537S None None None None p.L536Q None None None None None None None None None None None c.1607_1608TC AG c.1610A C c.1609T C c.1613A G c.1613A G c.1613A G c.1613A G c.1607T A c.1610A C c.1610A C c.1610A C c.1610A C c.1610A C c.1607T A c.1610A C c.1610A C ��-Ionone Activator Sequencing NGS ddPCR Y537S depth (Freq ) (Freq ) 2695 1995 1994 1984 1881 1970 1534 1988 525 1993 1936 1443 1991 1476 1988 1232 200 1987 1300 1988 201 1888 1997 1984 1996 113 1977 1992 1982 1459 1142 1995 1991 1995 376 135 252 1734 1931 1427 851 990 1889 1976 495 1921 1857 1811 1990 1983 1999 1992 1822 1960 — 94 83 — 34 — 23 — — — — 81 — — 16 87 18 — — 12 18 — — 29 — — 12 35 — 17 — — — — — — — 40 — — — — 65 — — — — — — — — — — — — 93.eight 80 — — — 25 — — — — 84 — — 16 88 34 — — — — — — — — — — — — — — — — — — — — 39 — — — — — — — — — — — — — — — — 14-Sep-15 27-Dec-13 17-Nov-15 16-Sep-08 28-Oct-13 None None — Y537S Y537C None — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — Metastasis biopsy date 17-Mar-15 Mutation in Metastasis NoneContinuedSCIENtIFIC RePORTS (2018) 8:4371 DOI:10.1038/s41598-018-22312-xwww.nature.com/scientificreports/Mutation in plasma just after E-Ice-COLD Sample S-129 S-130 S-131 S-132 Blood sampling date 9-May-17 29-May-17 29-May-17 29-May-17 Varianta None None None None Sequencing NGS ddPCR Y537S depth (Freq ) (Freq ) 1930 987 1561 1362 — — — — — — — — Metastasis biopsy date Mutation in Metastasis — — — –Table 3. ESR1 variants in plasma cfDNA of metastatic BC patien.
Posted inUncategorized